INSTITUTE FUNDING OPPORTUNITIES

The Infectious Diseases Institute (IDI) is committed to advancing infectious diseases and microbiology research. The following funding supports partnerships across institute members and Ohio State’s infectious diseases and microbiology community:

Interdisciplinary Research Seed Grant Guidelines (downloadable PDF)
Seed grant funding is available for research initiatives intended to foster interdisciplinary collaborative efforts and to enhance competitiveness for defined extramural support for the purposes of growth.

Internal Event Funding Guidelines (downloadable PDF)

Events funding is available for activities that are interdisciplinary, support student or trainee development, advance an infectious diseases or microbiology area of study, and/or increase awareness of Ohio State’s Infectious Diseases Institute, and its infectious diseases and microbiology community.

Targeted Investing Funding Guidelines (downloadable PDF)
Funding is available for targeted investments intended to support initiatives that have the potential to be uniquely transformative; or significantly enhance key, long-term strategic priorities identified by the institute’s executive committee.

Applicants for the above funding opportunities are required to be IDI members. Not a member?  JOIN THE INSTITUTE →

ADDITIONAL FUNDING RESOURCES AND TOOLS

Ohio State Office of Research Funding Opportunities and Research Database

Ohio State Office of Research Internal Funding Opportunities

National Science Foundation Outreach Activities

Academic Research Funding Strategies

Research Development and Grant Writing Newsletter
(Ohio State login required)

Research Funding Opportunities Consultations

If you are thinking about your next research project, we encourage you to schedule a research funding consult and learn how to use SPIN, an extensive research funding opportunity database. SPIN contains over 40,000 opportunities from more than 10,000 sponsors. 

Looking for a NIH Program Official in Your Research Area?

For years researchers have used the Matchmaker feature in NIH RePORTER to identify NIH-funded projects similar to their supplied abstracts, research bios, or other scientific text. Matchmaker was recently enhanced to make it just as easy to identify NIH program officials whose portfolios include projects in your research area.

After entering your scientific text (up to 15,000 characters), Matchmaker will analyze the key terms and concepts to identify up to 500 similar projects. Those projects will continue to show on the Projects tab with handy charts to visualize the results and quickly filter identified projects by Institute/Center, Activity Code, and Study Section. A new Program Official tab identifies the program officials associated with the matched projects and includes its own filters for Institute/Center and Activity Code. From the list of program officials you are one click away from their contact information and matched projects in their portfolios. Never before has it been so easy to answer the question “Who at NIH can I talk to about my research?”  Learn more

INTERNAL FUNDING OPPORTUNITIES

Campus-wide Internal Funding Opportunities

The OSU CCTS is excited to announce that The OSU Office of Research’s CarmenWiki listing of all internal funding opportunities has been updated with a new column titled “Includes Human Health”. Thanks to Jeff Agnoli and his team, this resource will now help translational scientists to quickly find grants that are applicable to human health.

 View all open opportunities

EXTERNAL FUNDING OPPORTUNITIES

Development of Therapeutic Products for Biodefence, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is the development of therapeutics for use in post-event settings following the intentional release of select pathogens, or in response to naturally-occurring outbreaks of infectious diseases caused by pathogens listed in the Technical Approach section. While proposals for the development of broad-spectrum therapeutics are encouraged, candidate therapeutics or lead series with a limited spectrum that target high-priority pathogens for which no standard clinical treatment exists or for which drug resistance poses a significant public health concern are eligible as proposed candidates/products or lead series

Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is the development of vaccines for scenarios associated with intentional release of a NIAID Category A, B, or C Priority Pathogen, or naturally-occurring outbreaks of infectious diseases caused by these pathogens or Zika virus (as a component of a multivalent vaccine for other pathogens such as a vaccine for Flavivirus family). Only proposed candidate products aimed at these pathogens are eligible. The candidate product(s) may also include an adjuvant that enhances the immune response (i.e., enhanced immunogenicity, decreased time, or reduced number of immunizations to achieve protective antibodies and/or increased efficacy). Adjuvants will be supported as components of the candidate product.

Collaborative Influenza Vaccine Innovation Centers (CIVICs)

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity ("universal influenza vaccines"). This funding will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials.

Advancing Evidence into Practice through Shared, Interoperable Clinical Decision Support Resources (U18)

PA-18-792

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

The goal of this funding opportunity is to conduct innovative research on broadly disseminating Patient-Centered Outcomes Research (PCOR) findings into clinical practice through clinical decision support (CDS) resources. Further, this opportunity aims to assist users of health IT focused on CDS through developing and building upon shareable, interoperable CDS resources such as those available on CDS Connect. Ultimately, AHRQ desires to have the CDS resources developed through these awards to be publicly-available, interoperable, and shareable on CDS Connect for further innovation, evaluation, and use in the field.

Health Services Research Projects (R01)

PA-18-792

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

Small Research Grant Program (R03)

PA-18-794

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

NIOSH Research Grant Programs

Small Grants (R03) PAR-18-797

Exploratory/Developmental Grant Program (R21) PAR-18-798

Occupational Safety and Health Research (R01) PAR-18-769

National Institute for Occupational Safety and Health (NIOSH)

July 19, 2018 for new applications; Standard dates apply for future dates (expires November 18, 2023)

NIOSH is an agency operating under the Centers for Disease Control and Prevention (CDC), with the mission of generating new knowledge in the field of occupational safety and health and transferring that knowledge into practice to prevent worker injury, illness and death. They fund a range of research including studies to reduce occupational exposure to infectious disease.

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)

PA-18-784

National Heart, Lung, and Blood Institute

Standard dates (expires September 8, 2021)

The objective of this FOA is to attract investigator-initiated multidisciplinary R01 research projects to define mechanistic interactions between the microbiome (gut/lung/oral or combinations) that influence normal physiology and pathophysiology of diseases within NHLBI's mission (see NHLBI Strategic Vision and mission). This FOA aims to address this gap in “causation,” leveraging the use of available biospecimens from existing cohorts and biobanks, using state of the art technologies (including high throughput sequencing, transcriptomics, proteomics, metabolomics, single cell profiles) and animal models, if applicable, with the goal to further our understanding of the complex microbiome-host interactions and functions.

Agriculture and Food Research Initiative Competitive Grants Program: Sustainable Agricultural Systems

RFA

USDA NIFA

Letter of Intent Deadline: June 27, 2018

Application Deadline: October 10, 2018

NIFA seeks creative and visionary applications that take a systems approach, and that will significantly improve the supply of abundant, affordable, safe, nutritious, and accessible food, while providing sustainable opportunities for expansion of the bioeconomy through novel animal, crop, and forest products and supporting technologies. These approaches must demonstrate current and future social, behavioral, economic, health, and environmental impacts. Additionally, the outcomes of the work being proposed must result in societal benefits, including promotion of rural prosperity and enhancement of quality of life for those involved in food and agricultural value chains from production to utilization and consumption.

Halting TB Transmission in HIV-Endemic and Other High-Transmission Settings (R01 Clinical Trial Not Allowed)

RFA-AI-18-037

NIAID

December 5, 2018

This funding opportunity will promote research to:

1) understand the critical drivers of TB transmission at the individual and population levels in high-burden settings, particularly where high incidence of HIV co-infection contributes to TB rates. (This may include the aerobiology of infectious particles and environmental- and population-based factors.)

2) develop potential interventions to prevent TB transmission in HIV-endemic and other high-transmission settings and to measure the rate of transmission underpinned by an increased understanding of the biomedical basis of transmission and related risk factors.

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)

PAR-18-840

NIH Fogarty International Center and NIAID

July 26, 2018 and July 25, 2019

The goal is to fund applications from U.S. and low- and middle-income country (LMIC) institutions that propose a collaborative training program to will strengthen the capacity of an LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.

Elucidating the Functional Roles of Non-Coding RNAs in Viral Infectious Diseases (R21 Clinical Trial Not Allowed)

RFA-AI-18-025

NIAID

November 15, 2018

The objective of this FOA is to stimulate hypothesis-driven research to facilitate transition of the ncRNA field from discovery toward a deeper mechanistic understanding of the function and regulation of ncRNAs, which will serve as a foundation for future translational research efforts. This FOA is intended to support research on both host and viral ncRNAs including, but not limited to, those involved in:

  • Viral transcription and replication
  • Regulation of host response to infection
  • Pathogenesis
  • Disease progression and severity
  • Response to vaccination or treatment

An emphasis will be placed on NIAID priority and emerging viral pathogens, and understudied classes of ncRNAs (e.g., long non-coding RNAs (lncRNAs), small nucleolar RNAs (snoRNAs), transfer RNA (tRNA) fragments).

Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV

PA-18-838 (R01 - Clinical Trial Optional)

PA-18-839 (R21 Clinical Trial Optional)

NICHD

Standard dates (expires September 8, 2021)

Objective is to examine the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure.

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)

PAR-14-193

NIH

July 26, 2018; July 25, 2019

This Funding Opportunity Announcement (FOA) encourages applications for the Global Infectious Disease (GID) Research Training Program from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of an LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs

Modeling and Simulation to Optimize HIV Prevention Research (MS OPR) (R01 Clinical Trial Not Allowed)

RFA-AI-18-026

NIAID

December 13, 2018

This FOA will support the development and validation of modeling and simulation methods and related tools to examine HIV transmission dynamics, make epidemic projections, and estimate the impact of HIV treatment and prevention. It is expected the modeling and simulation objectives can be achieved in a three-year project period. Funding for the final fourth year is dependent upon achieving applicant-proposed and pre-award negotiated "Go/No-Go criteria".

Approaches for Understanding Disease Mechanisms and Improving Outcomes in TB Meningitis (TBM) (R01 Clinical Trial Not Allowed)

PAR-18-822

NIAID and NIMH

September 4, 2018, September 4, 2019, September 4, 2020

This FOA will support hypothesis-based clinical and preclinical/non-clinical research studies focused on: 1) Identifying pathogenic and immunopathogenic mechanisms in the context of CNS-TB in in vitro and appropriate animal models that impact TBM disease development, progression, and outcomes, as well as the effect of HIV co-infection on these mechanisms; 2) Assessing molecular targets in pathogenic and immunopathogenic mechanisms leading to discovery or confirmation of targets for HDT; and 3) Evaluating new/repurposed antimicrobial drugs and/or dosing of current antimicrobials that are optimized for TBM treatment for use in combinations to more rapidly clear the infection.

Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)

RFA-DK-18-009

NIDDK

March 14, 2019

This FOA seeks interdisciplinary studies, led by Multiple-PD/PI teams, on the effects of HIV or its treatment within the GI tract. The emphasis is on fundamental mechanisms within the GI tract that impact HIV infection and persistence, GI immune or microbial homeostasis, enteropathy, disease progression, and the development of important comorbidities. The team must include at least one PD/PI whose expertise is primarily on an aspect of HIV related to the proposed project and at least one PD/PI with appropriate expertise in an aspect of GI pathobiology. 

HIV-Focused Population Surveys in Countries Supported Under the President's Emergency Plan for AIDS Relief (PEPFAR)

CDC-RFA-GH19-1941

CDC

August 14, 2018

This opportunity will provide funding and technical assistance for HIV-focused, household-based surveys in national and subnational general populations of all ages in PEPFAR countries. The secondary purpose is for HIV focused surveys and population size estimation of key and priority populations. These activities serve to assess program impact to inform national and local responses to HIV, mostly located in sub-Saharan Africa. These surveys estimate HIV prevalence and incidence, viral load, drug resistance, and other biomarkers, inform the uptake of prevention and treatment services, and estimate progress towards population-level UNAIDS 95-95-95 targets. The surveys may also measure diseases and health conditions related to HIV such as TB, hepatitis and syphilis to inform compatible public health action. This survey NOFO aims at generating high quality laboratory and interview data using standardized methods, strengthening local survey capacity, ensuring publicly accessible data to improve public health programs, and creating specimen repositories for future study. Key populations are sex workers, men who have sex with men, transgender women, people who inject drugs, and prisoners. Priority populations include country-specific groups shown to be at greater risk of HIV such as partners of sex workers, fisherfolk, and adolescent girls and young women.

The Role of Epitranscriptomics in Development and Disease

PAR-18-830 (R01 - Clinical Trial Not Allowed)

PAR-18-831 (R21 - Clinical Trial Not Allowed)

NICHD, NCI and NEI

November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021

These FOAs promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions. (Note that – as always – proposals must be relevant to the scientific mission of the participating institutes.)

Ecology and Evolution of Infectious Diseases (EEID)

NSF 16-592

Jointly sponsored by NSF, NIH and USDA

November 21, 2018

The EEID program supports research on the ecological, evolutionary, and socio-ecological principles that influence the transmission dynamics of infectious diseases. The program's focus is on the discovery of general principles and processes and on building and testing models that elucidate these principles. Projects must address quantitative or computational understanding of pathogen transmission dynamics, and must be an interdisciplinary effort that brings together such areas as anthropology, bioinformatics, computational science, ecology, economics, epidemiology, evolution, food science, genomics, geography, global health, mathematics, medicine, microbiology, plant science, population biology, sociology, physical environmental sciences, systems science, and veterinary medicine.

Agriculture and Food Research Initiative Competitive Grants Program: Foundational and Applied Science Program
RFA

USDA NIFA

Letter of Intent and Application Deadline: Varies by Program Area (see RFA for details)

In FY 2018, applications are sought in the following priority areas, a number of which have relevance for infectious disease research. See the RFA for details.

  1. Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
  2. Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
  3. Food safety, nutrition, and health (including Improving Food Safety and Understanding Antimicrobial Resistance)
  4. Bioenergy, natural resources, and environment;
  5. Agriculture systems and technology; and
  6. Agriculture economics and rural communities

2018 NIAID Omnibus Broad Agency Announcement

BAA

Proposals due August 10, 2018

Solicited products are anticipated to include: Antibacterial Therapeutics; Antiviral Therapeutics; and, Anti-toxin Therapeutics.

  1. Plant health and production and plant products (including Agricultural Microbiomes in Plant Systems and Natural Resources)
  2. Animal health and production and animal products (including Animal Nutrition, Growth and Lactation, and Animal Health and Diseas

Investigators in the Pathogenesis of Infectious Disease

Call for proposals

Burroughs Wellcome Fund

Pre-proposals due July 16, 2018 (with invited applications due November 15)

The PATH award provides $500,000 over a period of five years for assistant professors to bring multidisciplinary approaches to shed light on the fundamentals that affect how colonization, infection, commensalism, and other relationships play out at levels ranging from molecular interactions to systemic ones. Microbiome-related proposals must be infectious disease focused to compete well in this program.

Approaches for Understanding Disease Mechanisms and Improving Outcomes in TB Meningitis (R01 Clinical Trial Not Allowed)

PAR-18-822

NIAID and NIMH

Standard dates (expires May 8, 2021)

To support clinical and preclinical/non-clinical research to improve our understanding of disease mechanisms in tuberculosis meningitis and to improve therapy in the presence or absence of HIV co-infection.

Research Starter Grants

Pharmacology/Toxicology

Pharmaceutics

Translational Medicine and Therapeutics

Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation

September 1, 2018

This award offers $100,000 in financial support to individuals beginning independent research careers at the faculty level.

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) PAR-18-630

NIAID, NIA and NIGMS

Deadlines April 10, 2018; December 7, 2018; March 7, 2019; December 7, 2019

This opportunity supports applications for conducting investigator-initiated, milestone-driven, long-term (6 or 7 year) incrementally funded clinical trials (all phases) and associated mechanistic studies. Examples of factors that may require a project period of 6-7 years include:

•Nature of disease under study, longer follow-up required to achieve clinical and mechanistic outcomes

•Number and diversity of study sites

•Number of participants necessary for study completion

•Availability of target pool for the study

•Known difficulty with participant recruitment and/or retention

•Complex regulatory requirements specific to the study

Robert E. Shope International Fellowship in Infectious Diseases
American Society of Tropical Medicine and Hygiene
Application window opens March 14, 2018 and closes April 18, 2018
For more information, see list of previous recipients and Frequently Asked Questions.

Investigator Studies Program (MISP) for Infectious Disease

Merck

Due dates varies – see description below

The Investigator Studies Program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research. The current MISP areas in infectious disease are:

Antimicrobial Stewardship proposals accepted until May 1, 2018

Bacterial Infections proposals accepted until August 1, 2018

Clostridium difficile proposals accepted until June 1, 2018 and August 31, 2018

CMV proposals accepted until June 1, 2018 and August 31, 2018

Fungal Infections proposals accepted until April 2, 2018; June 1, 2018; and September 7, 2018

Hepatitis C proposals accepted on a monthly basis through December 2018

HIV proposals accepted until March 30, 2018

Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development
Grand Challenge RFP

Gates Foundation

Deadline June 22, 2018

The goal of this Grand Challenge is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic. Pilot Awards are $250,000 up to $2 million. Promising pilot projects may be invited to apply for up to $10 million. Interested applicants should contact Jason Phillips (Director, Foundation Relations, Phillips.814@osu.edu) as well as your sponsored programs officer. Jason’s team is available to discuss proposal ideas and review drafts.

Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development
PA-18-724 (R21 Clinical Trial Not Allowed)
PA-18-725 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires May 8, 2021)

The purpose of this FOA is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Advancing Evidence into Practice through Shared, Interoperable Clinical Decision Support Resources (U18)

PA-18-792

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

The goal of this funding opportunity is to conduct innovative research on broadly disseminating Patient-Centered Outcomes Research (PCOR) findings into clinical practice through clinical decision support (CDS) resources. Further, this opportunity aims to assist users of health IT focused on CDS through developing and building upon shareable, interoperable CDS resources such as those available on CDS Connect. Ultimately, AHRQ desires to have the CDS resources developed through these awards to be publicly-available, interoperable, and shareable on CDS Connect for further innovation, evaluation, and use in the field.

Health Services Research Projects (R01)

PA-18-792

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

Small Research Grant Program (R03)

PA-18-794

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires May 8, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

NIOSH Research Grant Programs

Small Grants (R03) PAR-18-797

Exploratory/Developmental Grant Program (R21) PAR-18-798

Occupational Safety and Health Research (R01) PAR-18-769

National Institute for Occupational Safety and Health (NIOSH)

July 19, 2018 for new applications; Standard dates apply for future dates (expires November 18, 2023)

NIOSH is an agency operating under the Centers for Disease Control and Prevention (CDC), with the mission of generating new knowledge in the field of occupational safety and health and transferring that knowledge into practice to prevent worker injury, illness and death. They fund a range of research including studies to reduce occupational exposure to infectious disease.

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)

PA-18-784

National Heart, Lung, and Blood Institute

Standard dates (expires September 8, 2021)

The objective of this FOA is to attract investigator-initiated multidisciplinary R01 research projects to define mechanistic interactions between the microbiome (gut/lung/oral or combinations) that influence normal physiology and pathophysiology of diseases within NHLBI's mission (see NHLBI Strategic Vision and mission). This FOA aims to address this gap in “causation,” leveraging the use of available biospecimens from existing cohorts and biobanks, using state of the art technologies (including high throughput sequencing, transcriptomics, proteomics, metabolomics, single cell profiles) and animal models, if applicable, with the goal to further our understanding of the complex microbiome-host interactions and functions.

Agriculture and Food Research Initiative Competitive Grants Program: Sustainable Agricultural Systems

RFA

USDA NIFA

Letter of Intent Deadline: June 27, 2018

Application Deadline: October 10, 2018

NIFA seeks creative and visionary applications that take a systems approach, and that will significantly improve the supply of abundant, affordable, safe, nutritious, and accessible food, while providing sustainable opportunities for expansion of the bioeconomy through novel animal, crop, and forest products and supporting technologies. These approaches must demonstrate current and future social, behavioral, economic, health, and environmental impacts. Additionally, the outcomes of the work being proposed must result in societal benefits, including promotion of rural prosperity and enhancement of quality of life for those involved in food and agricultural value chains from production to utilization and consumption.

Antimicrobial Stewardship in the Asia-Pacific Region

RFP

Pfizer

LOI due May 4, 2018

Full proposals (if invited) due August 3, 2018

Pfizer is seeking quality improvement research, health services research and/or educational research applications that identify and evaluate practices for successfully implementing key elements of antimicrobial stewardship programs within hospitals and other healthcare organizations.

Research Grants
Call for proposals

Cystic Fibrosis Foundation

May 8, 2018 and December 3, 2018

Research grants are intended to support basic science research. Studies may be carried out at the subcellular, cellular, animal, or patient levels. To be considered, proposals must be hypothesis-driven and provide sufficient preliminary data to justify Cystic Fibrosis Foundation support. Support is available for $125,000 per year (plus 8 percent for indirect costs) for up to two years. Priority will be placed on those projects that propose to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat CF.

Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) PAR-18-633

NIAID

Initial deadlines May 14, 2018; September 13, 2018; and January 14, 2019 (with additional dates through January 2021)

This opportunity encourages cooperative agreement applications for implementation of investigator-initiated, milestone driven, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. A clinical trial is defined by NIH as a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. In addition, any research study that will require regulatory oversight such as IND or IDE would be in scope.

Antibiotic Use & Resistance
Spring 2018 RFP

National Pork Board

May 22, 2018

Proposals are solicited in the areas of Alternatives to Antibiotics, Antibiotic Administration, and Mitigations. See RFP for additional details.

Rule of Life: Forecasting and Emergence in Living Systems (FELS)

The Dear Colleague Letter (DCL): Rule of Life: Forecasting and Emergence in Living Systems (FELS) section on conference proposal. The workshop proposals are due on June 1. I think conferences that focus on microbial topics and how they inform the rules of life would be a good way to move microbial science forward. Off the top of my head, I can think of workshops on the emergence of multicellularity from a unicellular life style, latency, dormancy, persistence in microbial ecology, and establishing phenotype from genotype in microbes may fit the DCL  Please find below the address of the webpage and the excerpt regarding the conferences:  

 https://nsf.gov/pubs/2018/nsf18031/nsf18031.jsp

RoL: FELS conference: These awards will provide up to one year of support for projects that do not exceed $100,000. PIs are encouraged to contact any relevant Program Director in a participating Directorate about suitability of the proposed conference prior to submission. RoL: FELS conference proposals may be submitted to any relevant program in a participating Directorate, but must include the prefix 'RoL:FELS' in front of the title. The deadline for submission of these proposals is June 1, 2018. received. RoL:FELS conference proposals should follow normal PAPPG guidance.

Contact Mamta Rawat, Ph.D., Program Director Physiological and Structural Systems Cluster, BIO/Integrative Organismal Systems, National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314, Ph. 703-292-7265, for additional information. 

Investigator-Initiated Genomic Medicine Research
PAR-18-735 (R01 Clinical Trial Optional)
PAR-18-736 (R21 Clinical Trial Optional)

National Human Genome Research Institute

June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020

This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.

Genomic Centers for Infectious Diseases (U19 Clinical Trial Not Allowed)

RFA-AI-18-004

NIAID

Deadline June 22, 2018

The purpose of this initiative is to promote broad use and expand the application of genomics technologies and computational analysis to understand infectious diseases, with an emphasis on pathogens, their interaction with the host and microbiome, and to aid in the development of novel genomics-based tools to diagnose, prevent and treat infectious diseases.

Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)

RFA-AI-18-010

NIAID

July 2, 2018

The purpose of this FOA is to establish, follow, and characterize longitudinal cohorts of infants to determine how initial and repeated natural influenza infections and/or influenza vaccinations shape infant and childhood immunity to future influenza exposures. The ultimate goal of this research is to provide key information to facilitate design of durable, broadly protective influenza vaccines.

Centennial Travel Award in Basic Science Tropical Disease Research
American Society of Tropical Medicine and Hygiene
Application window opens June 6, 2018 and closes July 11, 2018
For more information, see list of previous recipients and Frequently Asked Questions.

NIOSH Occupational Safety and Health Research R01 FOA: https://grants.nih.gov/grants/guide/pa-files/PAR-18-769.html

New Applications Due July 6, 2018 

Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional) RFA-DA-19-003

NIDA

Deadlines July 17 2018; July 17, 2019; and July 17, 2020

This initiative will support Omics studies (e.g. transcriptomic, epigenomic, epitranscriptomic, proteomic, metabolomic, nucleomic, high throughput imaging or functional testing, etc.) to address outstanding questions regarding HIV latency or reservoirs in the context of chronic substance use. These studies could be performed on tissues, body fluids, or single cells. The R61/R33 grant mechanism includes an exploratory high risk/high pay off R61 phase (three years).  Near the end of the R61 phase, NIDA scientific staff will review progress made towards the proposed R61 milestones and recommend a subset of R61 projects for continued support through the R33 phase (two years) pending merit and the availability of funds.  Applicants must propose both an R61 and an R33 phase in order to be responsive to this RFA.

Next-Generation Biologics for Sustained HIV Remission (R01 Clinical Trial Not Allowed)

RFA-AI-18-017

NIAID

NIMH

July 27, 2018

NIAID is encouraging research on and the early development of next-generation biologic drugs that alone or in combination with cART can induce a long-lasting HIV remission. In this context, next-generation biologics are defined as biologic molecules that either consist of novel single molecules or of novel conjugates between biologics, drugs, and toxins.

 Vaccine Adjuvant Discovery Program NIAID-DAIT-NIHAI201700100

NIAID

Deadline July 31, 2018

The purpose of this program is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines by either (a) exploiting the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) acting directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens.

Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases
American Society of Tropical Medicine and Hygiene
Application window opens June 20, 2018 and closes August 8, 2018
For more information, see list of previous recipients and Frequently Asked Questions.

NIH Funding Opportunity (R21) - Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms https://grants.nih.gov/grants/guide/pa-files/PAR-18-781.html

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

LOI due August 4th, 2018

Ecology and Evolution of Infectious Diseases (EEID) NSF 16-592

A joint program of NSF, NIH, and USDA

Due November 21, 2018

This program supports research on the ecological, evolutionary, and socio-ecological principles and processes that influence the transmission dynamics of infectious diseases. Projects should be broad, interdisciplinary efforts focused on principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Examples of relevant work includes: the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the cultural, social, behavioral, and economic dimensions of disease transmission.

NRSA Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31) PA-18-666

NIH

Standard dates (expires January 8, 2021)

This program supports mentored research training leading to a doctoral degree in the biomedical, behavioral, or clinical sciences for individuals from diverse population groups, with the goal of enhancing diversity of the research workforce in the US.

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)
PAS-18-698

National Institute of Diabetes and Digestive and Kidney Diseases

Standard AIDS deadlines (expires January 8, 2021)

This funding opportunity invites HIV/AIDS research projects within the mission of the NIDDK that address NIH's high priority HIV topics. Systemic complications of HIV infection directly affect many of the organ systems and processes within the research mission of the NIDDK (including diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases).  Moreover, NIDDK-relevant organs and tissues play central roles in HIV establishment, spread, persistence, and transmission. 

Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

PAR-18-651, (R01, Clinical Trial Optional)

PAR-18-652, (R21, Clinical Trial Optional)

PAR-18-653, (R34 Clinical Trial Optional)

NIMH (all), NIDA (all), NIAID (R01 and R21 only) and NIMHD (R01 only)

Standard dates (expires January 8, 2021)

These opportunities encourage developmentally tailored research that incorporates recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.

Support for Conferences and Scientific Meetings (Parent R13, Clinical Trial Not Allowed) PA-18-648

Many NIH Institutes including NIAID

Standard dates (expires January 8, 2021)

This opportunity supports high quality scientific conferences such as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge.

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity
PA-18-754 (R21 Clinical Trial Not Allowed)
PA-18-753 (R01 Clinical Trial Optional)

NIAID

Standard AIDS deadlines (expires May 8, 2021)

The purpose of this FOA is to stimulate development of novel HIV biomarkers and new/improved HIV-1 incidence assays and algorithms to differentiate individuals with recent HIV-1 infections (within the previous year) from chronic infections.  The ideal assay(s) and/or algorithm(s) should provide 95% or greater specificity and increase reliability for distinguishing incident from chronic HIV infections, regardless of whether the incident or chronic cases are taking antiretroviral therapy (ART).

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression
PA-18-738(R01 Clinical Trial Optional)
PA-18-739 (R21 Clinical Trial Optional)

NCI, NIA, NIDCR, and NINR

Standard dates (expires May 8, 2021)

The overall purpose of this FOA is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health
PA-18-722 (R01 Clinical Trial Optional)
PA-18-723 (R21 Clinical Trial Optional)

Multiple NIH Institutes including NIAID

Standard dates (expires May 8, 2021)

The NIAID is interested in supporting programs that support the development of biomedical measures to improve adherence to ART, PrEP, and other HIV prevention interventions and strategies.  NIAID is also interested in supporting basic and applied research in the behavioral and social sciences to inform the development of novel interventions that enable all HIV infected individuals to achieve durable viral suppression.

Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development
PA-18-724 (R21 Clinical Trial Not Allowed)
PA-18-725 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires May 8, 2021)

The purpose of this FOA is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

NIAID Funding Opportunity (Presolicitation) - Large-scale T-cell immune epitope discovery 

https://www.fbo.gov/spg/HHS/NIH/NIAID/BAA-NIAID-DAIT-NIH-AI201800007/listing.html

Solicitation Number: BAA-NIAID-DAIT-NIH-AI201800007

Notice Type: Presolicitation

Synopsis: Added: Apr 18, 2018 3:02 pm

Introduction 

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (HHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology and Transplantation has a requirement for the discovery of T cell immune epitopes that are important in 1) protection of humans from infectious diseases 2) pathogenesis of autoimmune diseases and 3) and rejection of, or tolerance to, transplanted cells/organs/tissues. 

Description

The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, commensal organisms, or alloantigen, and validation of these epitopes regarding their role in immune protection or immune-mediated pathogenesis in humans. Investigators may also include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), or clinicians with expertise in the target autoimmune disease(s) or transplantation, as appropriate. This program will not support studies related to HIV/AIDS or allergen epitopes (including infection-related allergen epitopes). 

 Investigators may utilize established technological advances for immune epitope discovery or develop new or improved technologies for the large-scale identification of novel T cell epitopes. For the purpose of this solicitation, large-scale immune epitope discovery is defined as methods that will allow for extensive identification and validation of a broad range of novel T cell epitopes. Immune epitope discovery methods must be accompanied by basic studies in human samples to validate identified epitopes as targets of T cell recognition. Investigators may, but are not required to, include studies in appropriate animal models. Supported investigators will be required to attend an annual program progress meeting at NIH and submit their epitope information, and novel epitope prediction algorithms if applicable, to the Immune Epitope Database and Analysis Resource (www.iedb.org). Solicitations will be evaluated for their scientific and technical merit, scientific and technical personnel, project management plan, and facilities and other resources available to accomplish the proposed studies.

 It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about August 30, 2019.  NIAID estimates that the average annual total cost (direct and indirect costs combined) is $1M per contract award. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five years. 

 Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about May 8th, 2018, and may be accessed through FedBizOpps (http://www.fedbizopps.gov/). This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

For this solicitation, the NIAID requires proposals to be submitted via two methods: (1) 

Disc (CD or DVD) and (2) online via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable. 

DoD Peer Reviewed Medical Research Program 

The vision of the FY18 PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address at least one of the FY18 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiologic, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition, and to develop and validate clinical care or public health guidelines.

 All applications for PRMRP funding must specifically address at least one of the Topic Areas as directed by Congress and must be directly relevant to the healthcare needs of military Service members, Veterans, and/or beneficiaries. Some Topic Areas of relevance:

  • Antimicrobial Resistance
  • Muscoskeletal Disorders
  • Hepatitis B and C
  • Vaccine Development for Infectious Diseases
  • Cardiomyopathy
  • Emerging Infectious Diseases
  • Inflammatory Bowel Diseases
  • Interstitial Cystitis
 

There are several awards available:

Focused Program Award

The PRMRP Focused Program Award mechanism is intended to optimize research and accelerate the solution for a critical question related to at least one of the Congressionally directed FY18 PRMRP Topic Areas through a synergistic, multidisciplinary research program. The anticipated total costs budgeted for the entire period of performance for an FY18 PRMRP Focused Program Award will not exceed $10M.

Investigator-Initiated Award

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY18 PRMRP Topic Areas.  The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. The data may be unpublished or from published literature.

 Discovery Award

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design.

 Technology Therapeutic Development Award

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY18 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.